Skip to main content
8897 search results for:

Urothelial Cancer 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 29-04-2024 | Thrombocytopenia | OriginalPaper

    Prediction Model for Severe Thrombocytopenia Induced by Gemcitabine Plus Cisplatin Combination Therapy in Patients with Urothelial Cancer

    Severe thrombocytopenia is often induced by combination therapy using gemcitabine and cisplatin (GC). Grade 3 or 4 thrombocytopenia was more frequent in patients receiving GC therapy than in those receiving methotrexate, vinblastine, doxorubicin …

  2. 10-05-2024 | Online First

    Comparative Analysis of Clinicopathologic Characteristics and Outcomes of Urothelial Bladder Cancer Between Young and Older Adults—Experience from a Tertiary Care Center

    The evidence on bladder cancer in the young population remains fragmented due to lack of literature and conflicting results from the existing studies. We aim to elucidate such conflicting data and define the clinicopathologic characteristics …

  3. 03-04-2024 | Online First

    Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer

    Urothelial bladder cancer (UBC) is one of the most common malignancies in the USA; it is the fourth most common cancer in men, and there will be an estimated 82,290 new cases and 16,710 deaths in 2023 [ 1 ]. Advanced urothelial carcinoma (aUC) is …

  4. 01-12-2024 | Cystectomy | OriginalPaper

    Predicting individual outcomes after radical cystectomy in urothelial variants with Cancer of the Bladder Risk Assessment (COBRA) score

    Bladder cancer (BC) is a heterogeneous disease that develops via distinct genetic pathways and differs in the distribution of oncogenic mutations among distinct histologic subtypes [ 1 ]. Urothelial carcinoma (UC) corresponds to approximately 90% …

  5. 22-03-2024 | Filgrastim | OriginalPaper

    Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022

    Granulocyte colony-stimulating factor (G-CSF) decreases the incidence, duration, and severity of febrile neutropenia (FN); however, dose reduction or withdrawal is often preferred in the management of adverse events in the treatment of urothelial

  6. 19-12-2023 | OriginalPaper

    Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer

    This study is the largest real-world study of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer and the only real-world study with overall survival results. Our effectiveness results, in terms …

  7. Open Access 12-12-2023 | OriginalPaper

    Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder Cancer: Survival Outcomes After Radical Nephroureterectomy

    The National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database was queried to identify patients with bladder cancer (International Classification of Diseases [ICD]-10 codes C67.0–C67.9) and subsequent UTUC (ICD-10 codes …

  8. Open Access 08-02-2024 | Cystectomy | Online First

    Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study

    High-risk (HR) and very HR non-muscle-invasive urothelial bladder cancer (NMIBC) frequently recurs, with a 60% risk in 12 months according to EORTC, and bears a substantial risk of disease progression [ 1 ]. According to an individual patient data …

  9. 04-12-2023 | Urothelial Cancer | OriginalPaper

    Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study

    Bladder cancer (BC) is the tenth most common cancer worldwide, with an estimated 573,000 new cases and 213,000 deaths in 2020 [ 1 ]. Urothelial cancer (UC) is the most prevalent form of BC, accounting for about 90% of cases involving the renal …

  10. 04-08-2023 | Urothelial Cancer | OriginalPaper

    Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution

    Urothelial carcinoma (UC) is the tenth most common malignant tumor diagnosed worldwide in both genders [ 1 ]. Among them, bladder cancer (BC) represents about 90% of UCs while upper urinary tract UCs and urethral cancers are infrequent. Overall …

  11. 31-10-2023 | Urothelial Cancer | Expert Interview | Article

    ESMO 2023: Advances in urothelial cancer

    Dr. Enrique Grande discusses the findings of the EV-302 trial of enfortumab vedotin plus pembrolizumab and the CheckMate 901 trial of nivolumab plus chemotherapy, both conducted in the advanced urothelial cancer setting.

  12. Open Access 01-12-2023 | Urothelial Cancer | OriginalPaper

    Effect of subsequent bladder cancer on survival in upper tract urothelial carcinoma patients post-radical nephroureterectomy: a systematic review and meta-analysis

    Upper urinary tract urothelial carcinoma (UTUC) is a rare malignant disease that accounts for 5–10% of all urothelial carcinoma [ 1 ]. Radical nephroureterectomy (RNU) with ipsilateral bladder cuff excision (BCE) remains the standard treatment for …

  13. Open Access 01-12-2023 | Schistosomiasis | OriginalPaper

    DNA methylation profiles in urothelial bladder cancer tissues and children with schistosomiasis from Eggua, Ogun State, Nigeria

  14. Open Access 01-12-2023 | Neutropenia | Letter

    Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

    Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor …

  15. Open Access 01-12-2023 | Biomarkers | OriginalPaper

    Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

    Urothelial bladder cancer (UBC) is the 10 th most prevalent cancer worldwide and the 4 th among men [ 1 ]. Long-term surveillance of patients at risk of recurrence or progression is costly for healthcare providers and burdensome for patients …

  16. 24-10-2023 | Urothelial Cancer | News | Article

    EV-302 heralds practice change for advanced urothelial cancer

    Combined treatment with enfortumab vedotin plus pembrolizumab has achieved an overall survival benefit in previously untreated advanced urothelial cancer.

  17. 25-07-2023 | Adenovirus | ReviewPaper

    Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

    Treatment options for nonmuscle invasive urothelial carcinoma of the bladder (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG) instillations are currently limited and often total resection of the bladder is the only therapeutic option for …

  18. Open Access 01-12-2023 | Cytostatic Therapy | OriginalPaper

    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial

    Urothelial cancer (UC) is the 10th most common cancer worldwide [ 1 ]. The current standard of care for patients with non-metastatic muscle invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy followed by removal of the …

  19. Open Access 01-12-2023 | Magnetic Resonance Imaging | OriginalPaper

    Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI

    Muscle-invasive bladder cancer (MIBC), albeit localized, is associated with elevated risk for metastatic dissemination and therefore disease-related morbidity and mortality [ 1 ]. Radical cystectomy is the gold standard for management of MIBC and …

  20. 31-05-2023 | Urothelial Cancer | ReviewPaper

    Antibody–Drug Conjugates in the Treatment of Urothelial Cancer

    Antibody–drug conjugates (ADCs) have transformed the treatment landscape in oncology and become an essential therapeutic modality. In urothelial carcinoma (UC), the two ADCs that have been especially successful in clinical practice are enfortumab …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.